Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 3/20 | 0.42 |
| ▸ | CELA1 | Q9UNI1 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5042710 | 0.89 | HTT (0.45) | PREPCELA1CYP3A4BACE1GAA | |
| SCHEMBL6768867 | 0.86 | CYP3A4 (0.38) | PREPCELA1CYP3A4BACE1 | |
| SCHEMBL17935193 | 0.86 | CA1 (0.46) | PREPCELA1BACE1HTTCA1 | |
| SCHEMBL8176820 | 0.84 | FABP3 (0.52) | HTTGABRA1 | |
| SCHEMBL9029438 | 0.84 | BACE1 (0.47) | CYP3A4BACE1HTTKDM4ETP53 | |
| SCHEMBL17935202 | 0.83 | CA1 (0.61) | PREPCELA1GAACA1CA2 | |
| SCHEMBL29113877 | 0.82 | HTT (0.38) | BACE1GAAHTTKDM4ETP53 | |
| SCHEMBL1928602 | 0.82 | GABRA1 (0.40) | HTTCYP1A2ADRA2ACYP2D6PKM | |
| SCHEMBL9090807 | 0.81 | THRA (0.45) | BACE1GAAKDM4EHSD17B10GABRA1 | |
| SCHEMBL9270934 | 0.79 | FNTA (0.42) | CYP3A4HTTKDM4ETP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6686389-B2 | KIDNEY DISEASE, ORGAN TRANSPLANT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2004-02-03 | — | — | US | disclosed |
| US-20020156296-A1 | 2,3-dihydrobenzofuran derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2002-10-24 | — | — | US | disclosed |
| US-6403639-B1 | POTENT CYTOPROTECTIVE AGENT WHICH INHIBITS LIPID-PEROXIDATION FOR PREVENTION AND TREATMENT OF VARIOUS RENAL DISEASES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2002-06-11 | — | — | US | disclosed |
| EP-0995437-A1 | 2,3-DIHYDROBENZOFURAN DERIVATIVES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2000-04-26 | — | — | EP | disclosed |
| EP-0445827-B1 | 4-Hydroxytetrahydropyran-2-one derivatives useful as cholesterol and lipid reducing agents | FUJIREBIO KK (JP) | 1996-09-25 | — | — | EP | disclosed |
| US-5149834-A | Anticholesterol agent and enzyme inhibitors, for curing arteriosclerosis | FUJIREBIO INC. (JP) | 1992-09-22 | — | — | US | disclosed |
| EP-0445827-A2 | 4-Hydroxytetrahydropyran-2-one derivatives useful as cholesterol and lipid reducing agents | FUJIREBIO INC. (JP) | 1991-09-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156296-A1 | 2,3-dihydrobenzofuran derivatives | CBR1, CYP2F1, NDUFAF2 | PREP 4121/4885CELA1 916/4885CYP3A4 1417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.